Related MeSH Hierarchy (5)
Diseases [C] » Nervous System Diseases [C10] » Central Nervous System Diseases » Spinal Cord Diseases » Amyotrophic Lateral Sclerosis
Diseases [C] » Nervous System Diseases [C10] » Neurodegenerative Diseases » Motor Neuron Disease » Amyotrophic Lateral Sclerosis
Diseases [C] » Nervous System Diseases [C10] » Neurodegenerative Diseases » TDP-43 Proteinopathies » Amyotrophic Lateral Sclerosis
Diseases [C] » Nervous System Diseases [C10] » Neuromuscular Diseases » Motor Neuron Disease » Amyotrophic Lateral Sclerosis
Diseases [C] » Nutritional and Metabolic Diseases [C18] » Metabolic Diseases » Proteostasis Deficiencies » TDP-43 Proteinopathies » Amyotrophic Lateral Sclerosis
Description
A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94) MeSH
Hierarchy View
Approved Indicated Drugs (4)
Phase 4 Indicated Drugs (2)
Phase 3 Indicated Drugs (23)
Phase 1 Indicated Drugs (37)
Other Experimental Indicated Drugs (14)
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (74)
California Institute for Regenerative Medicine
California Pacific Medical Center Research Institute
Carolinas MDA Neuromuscular/ALS Center-Carolinas Medical System
Katholieke Universiteit Leuven
Laboratoire français de Fractionnement et de Biotechnologies
National Institute of Neurological Disorders and Stroke (NINDS)
Princess Beatrix Muscle Foundation
State University of New York, Syracuse
Universidad Autonoma de Nuevo Leon
Organization Involved with Phase 2 Indications (145)
ALS Therapy Development Institute
Andalusian Initiative for Advanced Therapies
Andalusian Initiative in Advanced Therapies
Bennett, James P., Jr., M.D., Ph.D.
Brain Chemistry Labs, Institute for EthnoMedicine
Catholic University of Sacred Heart, Rome
Center for Neurologic Study, La Jolla, California,
Centre Hospitalier Universitaire de Nīmes
El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Forbes Norris MDA/ALS Research Center
Fundación Universidad Católica de Valencia San Vicente Mártir
Genervon Biopharmaceuticals, LLC
Hoosier Cancer Research Network
IRCCS National Neurological Institute C. Mondino Foundation
Isfahan neurosciences research center
Muscular Dystrophy Association
National Center for Complementary and Integrative Health (NCCIH)
National Center for Research Resources (NCRR)
Neuraltus Pharmaceuticals, Inc.
Neurogen Brain and Spine Institute
Office of Dietary Supplements (ODS)
Phil Smith Neuroscience Institute at Holy Cross Hospital
Phoenix Neurological Associates, LTD
Polski Bank Komorek Macierzystych JSC (PBKM)
Royal Brisbane & Women's Hospital
South Shore Neurologic Associates
Universidad Católica de Valencia
University Hospital Motol, Prague, Czech Republilc
University of California, San Francisco
University of Campania Luigi Vanvitelli
University of Eastern Piedmont
University of Modena and Reggio Emilia
University of Naples Frederico II
University of Texas at Houston
Organization Involved with Other Experimental Indications (15)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
